Answers are grounded in this paper and cite their sources.
Sugammadex is the first selective antagonist to reverse neuromuscular blockade induced by rocuronium and vecuronium. The mechanism by which sugammadex works is superior to current neuromuscular block reversal strategies in terms of speed, efficacy and side effects. There is little contemporary guidance on the use of sugammadex in intensive care medicine. This review covers the key pharmacological features, clinical uses and cost-effectiveness in the context of intensive care practice.
No takes yet. Share an insight, caveat, or question.
Karalapillai et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: